Haemonetics Shares Jump Over 17% Following CSL Plasma Deal Update

By EC Assets · Published 8 October 2026

Haemonetics Corporation shares rose significantly in premarket trading on Thursday. The medical technology company's stock jumped over 17%. This movement followed an update on its supply agreement with CSL Plasma Inc. Haemonetics has a supply agreement with CSL Plasma. Yahoo Finance reported that Haemonetics shares rose after signing a supply agreement with CSL Plasma. This suggests the update involved the signing of a new agreement or a significant development concerning an existing one. The company's plasma business drives organic growth. Haemonetics reported improved gross and operating performance. Its plasma business contributes to robust profit margins and strong cash flow. Haemonetics raised its 2026 guidance. It projects 7% to 10% organic growth, excluding CSL Plasma. This projection is amid strong performance in its plasma and hospital segments. The second quarter saw growth propelled by share gains. CSL Plasma is a significant player in the plasma collection industry. Haemonetics' relationship with CSL Plasma is a key element of its business strategy. Updates to this agreement can influence investor sentiment. The medical technology sector continues to see activity related to supply chain agreements. These agreements are crucial for companies relying on specific inputs or distribution channels. Investor focus often remains on such strategic partnerships and their financial implications. Investors will monitor further announcements regarding Haemonetics' supply agreements and financial guidance. Future updates on organic growth projections and plasma collection trends will also be relevant. This article is intended for informational purposes only. It does not constitute investment advice.